INVO Bioscience, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (Nasdaq: INVO) on January 10, 2024, covering events occurring on December 29, 2023, and January 4, 2024. The filing details a material definitive agreement and the closing of the first tranche of a private equity offering with NAYA Biosciences, Inc. ("NAYA").
Key Financial Metrics and Transaction Details
The filing reports the following specific financial data related to the equity transaction:
- Transaction Type: Private placement of Series A Preferred Stock.
- Investor: NAYA Biosciences, Inc.
- Price Per Share: $5.00.
- Total Agreement Size: 1,000,000 shares (Total value $5,000,000).
- First Tranche Closing (Jan 4, 2024): 100,000 shares sold for gross proceeds of $500,000.
- Remaining Tranches: Four additional tranches of $500,000 each scheduled through February 16, 2024, plus a potential additional amount to support operations and cover past due payables.
The filing text does not provide clear values for the Company's overall revenue, net profit, operating cash flow, gross margins, total debt, or general liquidity position outside of the specific proceeds from this transaction.
Material Changes and Strategic Context
The primary material change is the entry into a Securities Purchase Agreement (SPA) with NAYA. This transaction is directly linked to a previously announced merger between INVO Bioscience, INVO Merger Sub, Inc., and NAYA. The funding structure is designed to:
- Support the Company's fertility business activities based on an agreed forecast.
- Provide liquidity for a 12-month period post-closing of the merger.
- Address past due accrued payables still outstanding.
Outlook, Risks, and Management Commentary
Management indicates that the funding is contingent on the closing of the merger and the Company's operational forecast. The agreement includes a provision for an additional funding tranche to be determined in good faith to ensure adequate support for the business. The sale of securities was made pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act of 1933.
Key Facts for Investor Verification
- Verify the status of the previously announced merger between INVO Bioscience and NAYA Biosciences.
- Confirm the schedule and conditions for the remaining four $500,000 tranches and the potential additional funding amount.
- Assess the magnitude of the "past due accrued payables" mentioned as a use of proceeds.
- Review the rights and preferences attached to the newly issued Series A Preferred Stock.
- Check for any subsequent filings regarding the closing of the remaining tranches or the merger.